Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Common Equity (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Common Equity data on record, last reported at $180.5 million in Q3 2025.

  • For Q3 2025, Common Equity fell 14.16% year-over-year to $180.5 million; the TTM value through Sep 2025 reached $180.5 million, down 14.16%, while the annual FY2024 figure was $198.1 million, 391.55% up from the prior year.
  • Common Equity reached $180.5 million in Q3 2025 per CTNM's latest filing, up from $171.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $217.5 million in Q2 2024 and bottomed at -$97.5 million in Q1 2023.
  • Average Common Equity over 3 years is $73.2 million, with a median of $171.4 million recorded in 2025.
  • Peak YoY movement for Common Equity: soared 492.38% in 2024, then fell 21.2% in 2025.
  • A 3-year view of Common Equity shows it stood at -$67.9 million in 2023, then surged by 391.55% to $198.1 million in 2024, then fell by 8.88% to $180.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $180.5 million in Q3 2025, $171.4 million in Q2 2025, and $184.8 million in Q1 2025.